Table 3. Benefit‐risk assessments of atezolizumab and pembrolizumab for first‐line use in cisplatin‐ineligible patients with advanced urothelial carcinoma at the time of initial accelerated approval.

Abbreviations: ORR, objective response rate; PD‐1, programmed death receptor‐1; PD‐L1, programmed death‐ligand 1.